Design preview. These 10 sample stories are real, recent news written to test the layout. The site stays out of search until launch.
biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
18:00 Veradermics’ oral minoxidil pill VDPHL01 meets Phase 3 goals in 536 men✦14:00 FDA approves bepirovirsen, a finite treatment for chronic hepatitis B✦15:00 Dave Asprey's first psychedelics conference draws about 600 to Austin✦14:00 Life Biosciences reports first human data for ER-100 reprogramming therapy✦14:00 Novo and Lilly report lower aging-clock readings on GLP-1 drugs✦14:00 High-dose NMN raised NAD+ in older adults but did not improve hearing✦14:00 Loyal's large-dog pill LOY-003 clears an FDA efficacy review step✦14:00 AI-designed drug rentosertib lowers aging-clock scores in small IPF trial✦18:00 Veradermics’ oral minoxidil pill VDPHL01 meets Phase 3 goals in 536 men✦14:00 FDA approves bepirovirsen, a finite treatment for chronic hepatitis B✦15:00 Dave Asprey's first psychedelics conference draws about 600 to Austin✦14:00 Life Biosciences reports first human data for ER-100 reprogramming therapy✦14:00 Novo and Lilly report lower aging-clock readings on GLP-1 drugs✦14:00 High-dose NMN raised NAD+ in older adults but did not improve hearing✦14:00 Loyal's large-dog pill LOY-003 clears an FDA efficacy review step✦14:00 AI-designed drug rentosertib lowers aging-clock scores in small IPF trial
STORY THREADS

Followed update by update.

Science moves in steps: a trial starts, enrolls, reads out, gets published, gets questioned. Each thread keeps those steps in order so you can see where a story stands.

Hair RestorationPhase 3 RCT · company dataVDPHL01 extended-release oral minoxidil1 report · latest Oct 21, 2026: Phase 3 Study 304 topline results
Breakthroughs & CuresFDA approval · Phase 3Bepirovirsen for chronic hepatitis B1 report · latest Oct 21, 2026: FDA approval as Hibsago
Protocols & BiohackingEvent · company claimsDave Asprey's BEYOND conference series1 report · latest Oct 15, 2026: First psychedelics conference held in Austin
Clinical TrialsPhase 1 · 3 patientsER-100 partial reprogramming trial1 report · latest Oct 9, 2026: First human data: 3 glaucoma patients, Day 56
Anti-Aging SciencePreprint + conference talkGLP-1 drugs and biological aging1 report · latest Oct 5, 2026: Novo and Lilly present aging-clock data at ARDD
Supplements & CompoundsRCT · 24 weeks · age 65+NAD+ precursor trials in humans1 report · latest Sep 26, 2026: 24-week NMN trial misses hearing endpoint
Anti-Aging ScienceFDA-CVM step · dogsLoyal's dog lifespan drugs1 report · latest Sep 17, 2026: LOY-003 efficacy (RXE) section accepted by FDA
AI & LongevityPhase 2a · post-hoc · n=42Insilico's AI-designed drug rentosertib1 report · latest Sep 8, 2026: Six proteomic aging clocks read younger on drug
Protocols & Biohackingn=1 · self-reportedBlueprint female protocol (Kate Tolo)1 report · latest Aug 25, 2026: Female protocol launched, 1,900 biomarkers planned
Clinical TrialsRCT preprint · 2 yearsMetformin and aging in human trials1 report · latest Jul 29, 2026: Two-year frailty RCT results posted as preprint